AR044078A1 - Dihidroquinazolinas sustituidas - Google Patents
Dihidroquinazolinas sustituidasInfo
- Publication number
- AR044078A1 AR044078A1 ARP040101391A ARP040101391A AR044078A1 AR 044078 A1 AR044078 A1 AR 044078A1 AR P040101391 A ARP040101391 A AR P040101391A AR P040101391 A ARP040101391 A AR P040101391A AR 044078 A1 AR044078 A1 AR 044078A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- cyano
- nitro
- alkoxy
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 125000003545 alkoxy group Chemical group 0.000 abstract 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 7
- 125000004414 alkyl thio group Chemical group 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- -1 cyano, hydroxy, amino Chemical group 0.000 abstract 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 241000701022 Cytomegalovirus Species 0.000 abstract 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10319612A DE10319612A1 (de) | 2003-05-02 | 2003-05-02 | Substituierte Dihydrochinazoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044078A1 true AR044078A1 (es) | 2005-08-24 |
Family
ID=33305099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101391A AR044078A1 (es) | 2003-05-02 | 2004-04-23 | Dihidroquinazolinas sustituidas |
Country Status (38)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319612A1 (de) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| DE10305785A1 (de) * | 2003-02-12 | 2004-08-26 | Bayer Healthcare Ag | Dihydrochinazoline |
| DE10320780A1 (de) * | 2003-05-09 | 2005-01-20 | Bayer Healthcare Ag | Heterocyclyl-substituierte Dihydrochinazoline |
| DE10352499A1 (de) * | 2003-11-11 | 2005-06-09 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline II |
| DE102004022672A1 (de) | 2004-05-07 | 2005-11-24 | Bayer Healthcare Ag | Substituierte Azachinazoline |
| DE102005027517A1 (de) * | 2005-06-15 | 2006-12-21 | Bayer Healthcare Ag | Verfahren zur Herstellung von Dihydrochinazolinen |
| DE102011101446A1 (de) * | 2011-05-10 | 2012-11-15 | Aicuris Gmbh & Co. Kg | Herstellung von "Dense Bodies" (DB) |
| DE102012101680A1 (de) | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
| DE102012101673A1 (de) | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| DE102012101659A1 (de) | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| ES2730958T3 (es) * | 2013-06-19 | 2019-11-13 | Aicuris Anti Infective Cures Gmbh | Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración oral |
| US9890128B2 (en) | 2013-12-12 | 2018-02-13 | Merck Sharp & Dohme Corp. | Process for making substituted quinazoline compounds |
| US10392353B2 (en) * | 2015-11-24 | 2019-08-27 | Merck Sharp & Dohme Corp. | Processes for making substituted quinazoline compounds using hydrogen bonding catalysts |
| WO2018028556A1 (zh) * | 2016-08-08 | 2018-02-15 | 南京明德新药研发股份有限公司 | 抗hcmv病毒化合物 |
| AU2019218150B2 (en) | 2018-02-08 | 2021-05-13 | Phaeno Therapeutics Co., Ltd. | Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method therefor |
| EP3527209A1 (en) * | 2018-02-16 | 2019-08-21 | UCB Biopharma SPRL | Pharmaceutical 6,5 heterobicyclic ring derivatives |
| WO2020053654A1 (en) | 2018-09-12 | 2020-03-19 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
| JP7417715B2 (ja) | 2019-09-26 | 2024-01-18 | ノバルティス アーゲー | 抗ウイルスピラゾロピリジノン化合物 |
| AR121437A1 (es) | 2020-02-27 | 2022-06-08 | Aic246 Gmbh & Co Kg | Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético |
| AR121440A1 (es) | 2020-02-27 | 2022-06-08 | Aic246 Gmbh & Co Kg | Un método de preparación de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, dicho compuesto y el uso del mismo para el tratamiento de infecciones virales |
| AR121439A1 (es) | 2020-02-27 | 2022-06-08 | Aic246 Gmbh & Co Kg | Un método para producir una forma cristalina de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato de sodio trihidrato |
| UY39095A (es) | 2020-02-27 | 2021-09-30 | Aic246 Gmbh & Co Kg | Composiciones farmacéuticas que comprenden acetato de 2- [(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio |
| UY39099A (es) | 2020-02-27 | 2021-08-31 | Aic246 Gmbh & Co Kg | 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo |
| EP3906929A1 (en) | 2020-05-08 | 2021-11-10 | AiCuris GmbH & Co. KG | Letermovir for use in the prevention and the treatment of coronavirus infections |
| CA3189271A1 (en) | 2020-08-17 | 2022-02-24 | Girij Pal Singh | A precipitation process for amorphous letermovir |
| CN115403528B (zh) * | 2021-05-27 | 2025-01-07 | 南京正大天晴制药有限公司 | 无定形3,4-二氢喹唑啉衍生物的制备方法 |
| CN114031560B (zh) * | 2021-11-16 | 2022-10-04 | 山东诚创蓝海医药科技有限公司 | 一种来特莫韦钠盐的制备方法 |
| AR128035A1 (es) | 2021-12-21 | 2024-03-20 | Aic246 Ag & Co Kg | Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio |
| WO2023185597A1 (zh) * | 2022-04-01 | 2023-10-05 | 上海迪赛诺化学制药有限公司 | 莱特莫韦中间体及其制备方法 |
| CN115322157B (zh) * | 2022-06-02 | 2023-12-05 | 浙江车头制药股份有限公司 | 来特莫韦中间体化合物及其制备方法和应用 |
| CN117229223A (zh) * | 2022-06-08 | 2023-12-15 | 苏州远智医药科技有限公司 | 一种杂环衍生物及其药物组合物、应用 |
| WO2025133248A1 (en) | 2023-12-21 | 2025-06-26 | Aic246 Ag & Co. Kg | Diastereomeric aminoalcohol and aminoether salts of 2-[(4r,s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl]acetic acid and their use for enantiomeric separation |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4320347A1 (de) | 1993-06-19 | 1994-12-22 | Boehringer Mannheim Gmbh | Quinazolin-Derivate und diese enthaltende Arzneimittel |
| US5854245A (en) * | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| DE19802437A1 (de) | 1998-01-23 | 1999-07-29 | Bayer Ag | Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe |
| AU748087B2 (en) | 1998-02-17 | 2002-05-30 | Tularik Inc. | Anti-viral pyrimidine derivatives |
| KR20010113820A (ko) | 1999-04-19 | 2001-12-28 | 시오노 요시히코 | 옥사디아졸 고리를 갖는 술폰아미드 유도체 |
| DE19930075A1 (de) | 1999-06-30 | 2001-01-04 | Bayer Ag | Neue Amino- und Amidosulfonamide als antivirale Mittel |
| US6730682B2 (en) * | 2000-07-12 | 2004-05-04 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| DK1325008T3 (da) * | 2000-07-31 | 2006-02-13 | Hoffmann La Roche | Piperazinderivater |
| EP1201765A3 (en) * | 2000-10-16 | 2003-08-27 | Axxima Pharmaceuticals Aktiengesellschaft | Cellular kinases involved in cytomegalovirus infection and their inhibition |
| WO2002085869A1 (de) | 2001-04-19 | 2002-10-31 | Bayer Aktiengesellschaft | Arylsulfonamide als antivirale mittel |
| DE10138578A1 (de) | 2001-08-06 | 2003-02-27 | Bayer Ag | Heterocyclylarylsulfonamide |
| DE10251914A1 (de) | 2002-11-08 | 2004-05-19 | Bayer Ag | Substituierte Chinazoline |
| DE10319612A1 (de) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| DE10305785A1 (de) * | 2003-02-12 | 2004-08-26 | Bayer Healthcare Ag | Dihydrochinazoline |
| DE10320780A1 (de) | 2003-05-09 | 2005-01-20 | Bayer Healthcare Ag | Heterocyclyl-substituierte Dihydrochinazoline |
| DE10352499A1 (de) * | 2003-11-11 | 2005-06-09 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline II |
| KR100610731B1 (ko) | 2004-02-24 | 2006-08-09 | 한국과학기술연구원 | Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법 |
| DE102004022672A1 (de) * | 2004-05-07 | 2005-11-24 | Bayer Healthcare Ag | Substituierte Azachinazoline |
| AU2006208084B2 (en) * | 2005-01-25 | 2012-07-26 | Prolexys Pharmaceuticals, Inc. | Quinoxaline Derivatives as Antitumor Agents |
| DE102005027517A1 (de) | 2005-06-15 | 2006-12-21 | Bayer Healthcare Ag | Verfahren zur Herstellung von Dihydrochinazolinen |
| BRPI0613604A2 (pt) * | 2005-07-21 | 2011-01-18 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptp-1b, e utilização dos compostos |
| DE102006009928A1 (de) | 2006-03-03 | 2007-09-06 | Aicuris Gmbh & Co. Kg | Substituierte Arylsulfonamide |
| DE102012101680A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
| DE102012101673A1 (de) | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| DE102012101659A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| ES2730958T3 (es) * | 2013-06-19 | 2019-11-13 | Aicuris Anti Infective Cures Gmbh | Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración oral |
-
2003
- 2003-05-02 DE DE10319612A patent/DE10319612A1/de not_active Withdrawn
-
2004
- 2004-04-17 DE DE502004003052T patent/DE502004003052D1/de not_active Expired - Lifetime
- 2004-04-17 PL PL04728119T patent/PL1622880T6/pl unknown
- 2004-04-17 NZ NZ543317A patent/NZ543317A/en not_active IP Right Cessation
- 2004-04-17 UA UAA200511418A patent/UA82519C2/uk unknown
- 2004-04-17 BR BRPI0410029A patent/BRPI0410029B8/pt not_active IP Right Cessation
- 2004-04-17 WO PCT/EP2004/004103 patent/WO2004096778A1/de active IP Right Grant
- 2004-04-17 DK DK04728119.1T patent/DK1622880T6/da active
- 2004-04-17 AU AU2004233978A patent/AU2004233978B2/en active Active
- 2004-04-17 MX MXPA05011707A patent/MXPA05011707A/es active IP Right Grant
- 2004-04-17 EP EP04728119.1A patent/EP1622880B3/de not_active Expired - Lifetime
- 2004-04-17 JP JP2006505178A patent/JP4733631B2/ja not_active Expired - Lifetime
- 2004-04-17 AT AT04728119T patent/ATE355280T1/de active
- 2004-04-17 PT PT04728119T patent/PT1622880E/pt unknown
- 2004-04-17 CN CNB2004800119284A patent/CN100393706C/zh not_active Expired - Lifetime
- 2004-04-17 SI SI200430301T patent/SI1622880T1/sl unknown
- 2004-04-17 CA CA2524069A patent/CA2524069C/en not_active Expired - Lifetime
- 2004-04-17 KR KR1020057020720A patent/KR100927063B1/ko not_active Expired - Lifetime
- 2004-04-17 ES ES04728119.1T patent/ES2284007T7/es active Active
- 2004-04-17 RU RU2005137276/04A patent/RU2360912C2/ru active
- 2004-04-23 AR ARP040101391A patent/AR044078A1/es active IP Right Grant
- 2004-04-26 US US10/832,109 patent/US7196086B2/en not_active Ceased
- 2004-04-28 UY UY28294A patent/UY28294A1/es not_active IP Right Cessation
- 2004-04-29 HN HN2004000146A patent/HN2004000146A/es unknown
- 2004-04-29 MY MYPI20041603A patent/MY144616A/en unknown
- 2004-04-30 PE PE2004000432A patent/PE20050145A1/es active IP Right Grant
- 2004-04-30 TW TW093112100A patent/TWI335912B/zh active
- 2004-04-30 CL CL200400930A patent/CL2004000930A1/es unknown
-
2005
- 2005-10-20 IL IL171513A patent/IL171513A/en active IP Right Grant
- 2005-10-27 ZA ZA2005/08710A patent/ZA200508710B/en unknown
- 2005-10-29 EG EGNA2005000688 patent/EG25273A/xx active
- 2005-11-01 EC EC2005006138A patent/ECSP056138A/es unknown
- 2005-11-02 CO CO05111848A patent/CO5700764A2/es active IP Right Grant
- 2005-11-08 MA MA28581A patent/MA27794A1/fr unknown
- 2005-11-30 NO NO20055649A patent/NO333265B3/no active Protection Beyond IP Right Term
-
2007
- 2007-03-26 US US11/728,896 patent/US8513255B2/en active Active
- 2007-05-25 CY CY20071100709T patent/CY1106476T1/el unknown
-
2015
- 2015-04-09 US US14/682,512 patent/USRE46791E1/en active Active
-
2018
- 2018-04-17 NL NL300933C patent/NL300933I2/nl unknown
- 2018-04-21 HU HUS1800018C patent/HUS1800018I1/hu unknown
- 2018-06-15 HU HUS1800028C patent/HUS1800028I1/hu unknown
- 2018-06-29 CY CY2018019C patent/CY2018019I2/el unknown
- 2018-07-04 NO NO2018022C patent/NO2018022I1/no unknown
- 2018-07-06 FR FR18C1029C patent/FR18C1029I2/fr active Active
-
2020
- 2020-07-21 US US16/934,363 patent/USRE49698E1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044078A1 (es) | Dihidroquinazolinas sustituidas | |
| AR054799A1 (es) | Derivados de oxindol | |
| AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| AR061739A1 (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR057906A1 (es) | Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta. | |
| AR053232A1 (es) | Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico. | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| AR066095A1 (es) | Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| ES2668775T3 (es) | Compuestos tetracíclicos | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| PE20151981A1 (es) | Pontenciador de inhibidores del homologo de zeste | |
| CO6140033A2 (es) | Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| AR053453A1 (es) | Derivados de aminoalquil- y amidoalquil-benzopirano substituidos | |
| AR059032A1 (es) | Combinacion de derivados de triazina y sensibilizadores de insulina | |
| AR070801A1 (es) | Derivados pirimidin -piridina | |
| UY29739A1 (es) | Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones | |
| PE20190106A1 (es) | Inhibidores del potenciador del homologo zeste 2 | |
| ECSP045420A (es) | Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos | |
| AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
| AR063577A1 (es) | Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos | |
| OA08023A (fr) | Nouvelles bis-(4-aminophényl)-sulfones substituées, leur préparation et leur utilisation en tant que médicament. | |
| AR059031A1 (es) | Combinacion de derivados de triazina e inhibidores de la hmg- coa reductasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |